We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.21 | -0.52% | 39.80 | 40.005 | 39.675 | 39.97 | 856,817 | 15:39:45 |
From Jul 2021 to Jul 2024
By Adam Clark
GlaxoSmithKline PLC said Tuesday that it and South Korean company SK Bioscience Co Ltd. have started a Phase 3 trial of their Covid-19 vaccine combination.
The British pharmaceutical company said the advance follows positive immunogenicity and safety data from earlier trials and that the partners are aiming for a global supply of the vaccine via the Covax facility in the first half of 2022, subject to data and regulatory review.
The trial combines SK Bioscience's vaccine candidate with GSK's adjuvant, an ingredient used to prompt a stronger immune response.
The randomized trial will enroll around 4,000 participants and compare the vaccine against the AstraZeneca PLC vaccine, with data due in the first half of 2022.
Write to Adam Clark at adam.clark@wsj.com
(END) Dow Jones Newswires
August 31, 2021 02:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
